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The baroreﬂex (BR) reﬂects autonomic blood pressure control. Alzheimer’s disease (AD) affects the
autonomic system. Detailed properties of BR in AD are unknown. We hypothesized that BR is reduced in
AD, and is inﬂuenced by autonomic effects of cholinesterase inhibitors (ChEI). BR was determined in 18
AD patients, 11 patients with mild cognitive impairment (MCI) and 19 healthy control subjects. In AD, BR
was measured again after ChEI treatment. Receiver operating characteristic analysis was used to deﬁne
a BR cutoff value, which was then tested in an independent validation sample of 16 AD, 18 MCI, and 18
control subjects. BR was lower in AD compared with MCI (p < 0.05) and in MCI compared with healthy
control subjects (p < 0.01). Receiver operating characteristic analysis between AD and healthy control
subjects yielded a sensitivity of 89% and a speciﬁcity of 94%. ChEI treatment increased BR with 66%
(p < 0.01). BR was reduced in AD and increased after treatment with ChEI. BR might be a good biomarker
to further explore the link between cardiovascular disease and AD.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder and is the leading cause of dementia. Worldwide, AD is
among the top 5 of most costly diseases and places a huge burden
on individual caregivers (Burns, 2000). There is still a limited
understanding of this disease and its underlying cause, which is
reﬂected in the lack of an effective curative treatment for AD.
Many of the currently developed and tested therapies are based
on the amyloid cascade hypothesis. This hypothesis, supported by
convincing genetic data, proposes that the extensive neuronal
damage in AD is caused by increased concentration and aggregation
of b-amyloid (Hardy and Higgins, 1992). However, this theory does
not offer an explanation for how this process is initiated in sporadic
forms of AD, nor for the observation that the earliest changes in AD
do not include amyloid deposition (Korczyn, 2008). Criticism
regarding the amyloid hypothesis has fueled the popularity of the
vascular hypothesis for AD, which states that cardiovascular disease
is an important causal or contributing factor in sporadic ADjmegen Medical Centre, 925
6500 HB, Nijmegen, The
408.
assen).
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evier OA license.(Iwamoto et al., 2003; Newman et al., 2005; Snowdon et al., 1997;
White et al., 2002).
Although cardiovascular factors are now commonly accepted as
risk factors for AD, the exact relationship between these factors and
AD remains poorly understood. For example, midlife hypertension
increases AD risk and antihypertensive treatment potentially
reduces this risk (in’t Veld et al., 2001; Launer et al., 2000), sug-
gesting a unidirectional, possibly causal relationship between
hypertension and AD. However, subjects with a parental history of
sporadic AD are more likely to have hypertension than control
subjects (van Exel et al., 2009), suggesting either a causal rela-
tionship between AD and hypertension or a shared causative factor.
Moreover, blood pressure (BP) levels decline from hypertension to
normotension or even to hypotension during the course of AD
(Skoog et al., 1996). These data imply a relationship wherein AD
might inﬂuence BP or BP might inﬂuence AD. Better understanding
of the relationship between BP control and AD might therefore
provide important new clues toward our understanding, and ulti-
mately, treatment, of AD.
A possible link between AD and BP is the baroreﬂex (BR). The BR
is a reﬂex loop with cardiac, vascular, and cerebral components
involved in short-term BP regulation (Lantelme et al., 2002). The BR
operates via the autonomic nervous system to restore sudden
changes in BP by changing heart rate (HR) or vascular tone. A
clinical example is the drop in BP on standing, which the BR
Fig. 1. Bivariate autoregressive model with exogenous input (ARXAR model) for the
description of the causal effects of systolic blood pressure (SBP) on R-R interval (RRi). In
the open loop scheme, RRi values are separately determined by the exogenous input
SBP and by SBP-unrelated variations described by the series u (Nollo et al., 2001).
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followed by peripheral arterial vasoconstriction (sympathetic acti-
vation). The cholinergic system is an important component of
cardiovascular and autonomic control, including the BR. This
cholinergic system is prominently affected early in AD (Perry et al.,
1977; Whitehouse et al., 1981). Therefore, we hypothesized that BR
function is reduced early in patients with AD (Medina et al., 1997).
In this study, we further explored this hypothesis in 3 steps.
First, we compared BR function between patients with AD, patients
withmild cognitive impairment (MCI), and healthy elderly subjects.
Patients withMCI are thought to represent patients with very early-
stage AD. The second step was to validate our ﬁndings in an inde-
pendent sample of AD patients, MCI patients, and elderly control
subjects. The third and ﬁnal step was to explore the role of the
cholinergic deﬁcit on BR function in AD, by testing the inﬂuence of
cholinesterase inhibitors on BR function in a subgroup of patients
with AD.
2. Methods
2.1. Study population
Overall, this study included 34 patients with mild to moderate
AD, 29 patients with MCI, and 37 healthy control subjects in 2
distinct samples: (1) a derivation sample: 18 patients with AD (72
6 years), 11 patients with MCI (71  9 years), and 19 healthy control
subjects (75  3 years), recruited at Radboud University Nijmegen
Medical Centre (RUNMC), and (2) a validation sample: 16 AD
patients (71  8 years), 18 patients with MCI (70  7 years), and 18
healthy control subjects (70  6 years) recruited at Maastricht
University Medical Center (MUMC). Data on cerebral hemody-
namics from the RUNMC AD patients and control subjects and from
the MUMC AD and MCI patients and control subjects have been
published recently (Gommer et al., 2012; van Beek et al., 2012).
In both samples, recordings of electrocardiograms (ECG) and
beat-to-beat photoplethysmographic BP were obtained. There was
a difference in body position during measurements between the 2
samples. Subjects at RUNMC were seated while ECG and BP were
recorded, whereas the subjects at MUMC were supine.
All subjects from both centers were examined by a geriatrician,
and carefully screened to exclude acute medical conditions. A
subset of subjects (15 control subjects; 15 MCI patients; 29 AD
patients) had a magnetic resonance imaging scan of the brain to
investigate medial temporal lobe atrophy. Informed consent was
obtained from all patients and healthy control subjects before they
entered the study. Both studies were approved by the medical
ethical committees of the corresponding centers.
Patients with MCI and ADwere diagnosed by a multidisciplinary
memory clinic team using the National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer’s Disease and
RelatedDisorders Association criteria (Blacker et al.,1994;McKhann
et al., 1984) and MCI consensus criteria (Winblad et al., 2004) based
on clinical evaluation and additional diagnostic tests if indicated,
such as magnetic resonance imaging scan of the brain, neuro-
psychological testing, and cerebrospinal ﬂuid analysis. In the deri-
vation sample fromRUNMC, BR in AD patients wasmeasured before
and after 8 weeks of treatment with a cholinesterase inhibitor
(galantamine, 4 weeks of 8mg followed by 4weeks of 16mg). In the
validation sample fromMUMC,10 of the 16ADpatientswere already
treated with cholinesterase inhibitors when BR was measured.
2.2. Data acquisition and preprocessing
The ECG was recorded using a 3-lead system and beat-to-beat
HR was obtained from each R-R interval identiﬁed from the QRScomplexes. Arterial BP was measured noninvasively at the middle
ﬁnger of the right hand using Finapres (Finapres Medical Systems)
at RUNMC and the Task Force Monitor (CN Systems) at MUMC. It
has been shown that BP measured on the ﬁnger by photo-
plethysmography is similar to conventional auscultatory measure-
ments on the upper arm (Imholz et al., 1991). For both systems, the
ﬁnger pressure cuff was positioned carefully at heart level with the
hand being held in the left midaxillary line. The hand and armwere
supported securely and comfortably with a sling. The subjects
underwent several minutes of customization and the servo-adjust
mechanism was turned off before recording. Periods of 100
seconds of artifact- and calibration-free data were selected by
visual inspection of the time series of the tachogram and systogram
and used for subsequent analysis. The time series were linearly
interpolated at 1 Hz to obtain equidistant time intervals. The time
series were detrended and ﬁltered with an eighth-order high-pass
Butterworth ﬁlter (0.02 Hz), to ascertain signal stationarity.
2.3. Causal model BR estimation
BR sensitivity is often evaluated noninvasively by assessing
heart rate variability (HRV) and systolic blood pressure (SBP) vari-
ability. However, studies using HRV and SBP variability often report
contradictory results (Allan et al., 2007; Collins et al., 2012; Zulli
et al., 2005). A possible explanation for this inconsistency is that
the estimation of the BR bymeans of HRV assumes but does not test
that the whole R-R interval (RRi) variability is generated by SBP
changes. Therefore the causal dependencies are not taken into
account. In this study, a bivariate causal model (ARXAR model),
which was ﬁrst introduced by Nollo et al. (2001), was used to
quantify the BR. With this model it is possible to describe the causal
relationship from SBP to R-R interval (the BR pathway) and to
separate it from the mechanical pathway (from RRi to SBP). Details
of this method are described elsewhere (Nollo et al., 2001).
In short, the interactions between R-R interval and systolic blood
pressure (SBP) are modeled as follows:
RRðnÞ ¼ 
Xp
k¼1
akRR
 
n k
!
þ
Xp
k¼1
bkSBP
 
n k
!
þ u
 
n
!
According to the ARXAR model, the RR series is affected by p
samples of its own past (by ak coefﬁcients) and by p samples of the
SBP sequence (by bk coefﬁcients). The effects of other sources
independent from SBP on R-R interval variability, considered as
noise in this context, are accounted for in themodel bymeans of the
u(n). As outlined in Fig. 1, the SBP and u signals are described as
autoregressive processes with WSBP and WRRi zero-mean input
white noises.
The blocks C and D are formed by the autoregressive parameters
of SBP and u, respectively. In the open loop ARXAR model the
variability of SBP around its mean value is considered as an
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without itself being affected by the R-R interval variability). The
coefﬁcient estimation follows an iterative identiﬁcation task based
on the generalized least squares method. The model order p was
chosen minimizing the Akaike ﬁgure of merit for the bivariate joint
process jRRi SBPj (Nollo et al., 2001). The gain of the R-R interval 
SBP transfer function (G(f)) was estimated directly from the coef-
ﬁcients of the A and B blocks. The value of the gain in the low
frequency band (0.04e0.15 Hz) was considered by sampling G(f) on
the low frequency peak of the spectrum of the driving SBP series
(Widesott et al., 2001). It has been shown that there is a good
agreement of the causal model with the traditional phenylephrine
test to determine baroreceptor responsiveness (Nollo et al., 2001).
2.4. Statistics
Results are presented as the mean  SD or percentage, unless
stated otherwise. Differences in baseline variables and BR between
control subjects and patients were evaluated with the Mann-
Whitney test for continuous variables and c2 statistics for propor-
tions. Sensitivity and speciﬁcity pairs for different BR values
distinguishing the groups were determined. These sensitivity and
speciﬁcity values were used to construct a receiver operating
characteristic (ROC) curve, in which the optimal sensitivity and
speciﬁcity combination is visualized. A p value < 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Derivation sample
3.1.1. Sample description
EighteenADpatients (11women),19age-matchedhealthycontrol
subjects (5 women), and 11 MCI patients (6 women) from RUNMC
participated in this study and had the BR measured successfully.
Table 1 summarizes the sample characteristics. AD and control
subjects did not differ with respect to SBP. However, SBP in MCI
patients was higher than in the healthy control subjects (p < 0.01).
3.1.2. BR function
BR function was calculated in correspondence with the peak in
the power spectra of the SBP between 0.04 and 0.15 Hz (dashed
line), the frequency range in which BR modulation of HR occurs.Table 1
Characteristics of derivation and validation sample
Derivation sample
Control (n ¼ 19) MCI (n ¼ 11) A
Age mean, y  SD 75  3 74  9 7
Sex (male/female) 14/5 5/6 7
MMSE (0e30), mean  SD 29  5 25  3a 2
MTA, mean 0.6 2
Hypertension, n (%) 4 (27) 7 (64)a 6
HR, bpm, mean  SD 62  8 60  12 7
SBP, mm Hg (mean  SD) 125  20 152  25a 1
Medication use
b-blocker 2 / 19 4 / 11 5
ACE inhibitor 0 / 19 0 / 11 3
ARB 0 / 19 0 / 11 1
Calcium channel blocker 0 / 19 1 / 11 2
Thiazide diuretic agents 3 / 19 0 / 11 4
Vasodilator 0 / 19 1 / 11 1
The results are reported as mean  standard deviation, absolute number, or frequencies
Key: ACE, angiotensin-converting enzyme; AD, Alzheimer’s disease; ARB, angiotensin rec
State Examination; MTA, medial temporal lobe atrophy; SBP, systolic blood pressure.
a Signiﬁcantly different (p < 0.05) from the control group of the same sample.
b Signiﬁcantly different from the matching group of the derivation sample.Mean values of the BR gain obtained by the ARXAR model
are shown in Fig. 2. BR was lower in AD (1.4  0.8 ms/mm Hg)
compared with control subjects (6.4  2.7 ms/mm Hg) (p < 0.01).
BR in MCI (2.9  0.7 ms/mm Hg) differed from both AD (p < 0.01)
and control subjects (p < 0.01) and was in between the values for
AD and control subjects. The area under the ROC curve for the
relationship between AD and healthy elderly was 0.92 (Fig. 3). With
a threshold (cutoff point) of 3.2 ms/mm Hg for AD, sensitivity was
89% and speciﬁcity was 94%.
3.2. Validation sample
3.2.1. Sample description
SBP and R-R interval data were obtained from 16 AD patients (9
women), 18 age-matched healthy control subjects (9 women), and
18 MCI patients (10 women) fromMUMC. Table 1 summarizes their
characteristics. In the derivation sample (RUNMC), MCI patients
had higher SBP than healthy control subjects. This was not the case
in the validation sample from MUMC. There were additional
differences between the derivation and validation sample: the
MUMC MCI group had lower SBP (133 mm Hg) than the RUNMC
MCI group (152 mm Hg) (p ¼ 0.02) and the MUMC control group
had a lower HR (58 bpm) compared with the RUNMC control group
(62 bpm) (p ¼ 0.04).
3.2.2. BR function
BR function was calculated in the same way as for the deriva-
tion sample. Mean values for BR gain obtained by the ARXAR
model are shown in Fig. 2 (dashed lines). Also, BR was lower in AD
(1.6  1.3 ms/mm Hg) compared with healthy control subjects (3.6
 0.8 ms/mm Hg) (p < 0.01). BR gain in the MCI group (2.3  1.4
ms/mm Hg) also was lower than in healthy control subjects
(p < 0.01), and higher than AD (p ¼ 0.03). Application of the BR
cutoff value of 3.2 ms/mm Hg, as it had been obtained in the
derivation sample, yielded a sensitivity of 93% and a speciﬁcity of
78% for differentiating AD from healthy control subjects in this
validation dataset (Table 2).
3.3. Cholinesterase inhibitors
In18ADpatients (11women) in thederivationsample, SBPandR-
R interval data were obtained before and after treatment with
cholinesterase inhibitors. After treatment with cholinesteraseValidation sample
D (n ¼ 18) Control (n ¼ 18) MCI (n ¼ 18) AD (n ¼ 16)
2  6 70  6 70  7 71  8
/11 9/9 8/10 7/9
2  5a 29  1 28  1b 21  4a
a
(33) 9 (50)b 6 (55) 7 (44)
1  12 58 6b 60  8 62  7
33  31 136  16 133  17b 133  15
/ 18 0 / 18 3 / 18 0 / 18
/ 18 0 / 18 0 / 18 0 / 16
/ 18 0 / 18 0 / 18 0 / 16
/ 18 0 / 18 0 / 18 0 / 16
/ 18 0 / 18 1 / 18 0 / 16
/ 18 0 / 18 0 / 18 0 / 16
.
eptor blocker; HR, heart rate; MCI, mild cognitive impairment; MMSE, Mini Mental
Table 2
Performance of the proposed baroreﬂex cutoff score
Baroreﬂex value Patients,
n (% of total)
AD Control Sensitivity Speciﬁcity
 3.2 ms/mm Hg 18 (51) 14 4 93% 78%
> 3.2 ms/mm Hg 17 (49) 1 14
Performance of the proposed baroreﬂex cutoff score to distinguish between Alz-
heimer’s disease (AD) and healthy control subjects, in the validation sample.
Fig. 2. Baroreﬂex (BR) values in mean  standard deviation for the 3 groups (mild
cognitive impairment [MCI] patients, patients with Alzheimer’s disease [AD], and
healthy age-matched control subjects; left graph). The solid lines represent the deri-
vation sample and the dashed lines represent the validation sample. Signiﬁcant
differences are indicated by the connecting lines (dashed for data of the derivation
sample, and solid for data of the validation sample).
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ms/mm Hg (p < 0.01). In the validation sample, no before and after
cholinesterase inhibitor treatment comparisons were available,Fig. 3. Receiver operating characteristic curve analysis of the predictive value of
baroreﬂex (BR) in distinguishing Alzheimer’s disease patients from healthy control
subjects. The area under the curve equals 0.92; 95% conﬁdence interval is 0.84-1.00;
p < 0.01. The square shows the optimal BR cutoff point at 3.2 ms/mm Hg resulting in
a sensitivity of 89% and a speciﬁcity of 94%.however in this sample, BR was higher in the 10 patients who were
treated with cholinesterase inhibitors (2.0  1.5 ms/mm Hg)
compared with the 6 patients who were not treated (0.89  0.4
ms/mm Hg) (p ¼ 0.02). Cholinesterase inhibitor-treated patients in
the derivation sample had a slightly higher BR than those in the
validation sample (p ¼ 0.03).
4. Discussion
The main ﬁnding of our study is that the BR function is lowered
in patients with AD compared with age-matched control subjects.
Our results are in agreement with the depressed BR sensitivity
observed in 24 patients with AD (Szili-Torok et al., 2001). Our study
adds to these observations by the addition of a group of patients
with MCI, reﬂecting early-stage AD, by reproducing our ﬁndings in
an independent sample, and by investigating the effect of cholin-
esterase inhibitors on BR. Furthermore, a more precise BR quanti-
ﬁcationmethod was used. The traditional sequence analysis used in
the study of Szili-Törok et al. (2001) assumes, but not tests, that the
whole R-R interval variability is generated by SBP changes. The
method used in our study takes this causal dependency into
account by dividing the R-R interval variability in SBP-related and
SBP-unrelated parts.
The difference in BR function was so prominent that it was
possible to distinguish patients with AD from control subjects by
their BR function. The discriminatory value of BR was so strong that
it achieved a performance that compares with or even exceeds that
of current diagnostic biomarkers, such as cerebrospinal ﬂuid anal-
ysis of amyloid b42. Indeed, a cutoff value for BR gain of 3.2 ms/mm
Hg reached a sensitivity of 89% and a speciﬁcity of 94% to
discriminate AD from control subjects in the derivation sample. For
comparison, cerebrospinal ﬂuid analysis of amyloid b42 has an ROC
of 0.9, with a sensitivity of 93% and a speciﬁcity of 87% to
discriminate AD from control subjects (Spies et al., 2010). This
discriminatory cutoff value for BR performed equally well in the
independent validation sample with a sensitivity of 93% and
a speciﬁcity of 78% for differentiating AD from healthy control
subjects. Additionally, MCI patients had a BR value that was inter-
mediate between control subjects and AD. A strength of our study is
that these results were also conﬁrmed in the independent valida-
tion sample.
These ﬁndings underscore the importance of exploring the
underlying mechanism that explains this association between
impaired BR functioning and AD. They raise the question whether
AD pathology results in impaired BR functioning or whether
impaired BR functioning contributes to (acceleration of) AD
pathology.
4.1. Possible mechanism and consequence of the decreased BR in AD
The BR is the major feedback control system for BP. Primary
afferent ﬁbers from arterial baroreceptorsdin the carotid sinus and
aortic archdsend information to the nucleus tractus solitarius in
the medulla oblongata (Dampney et al., 2003). From here, infor-
mation is sent via interneurons to the hypothalamus or to higher
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insular cortex (Sykora, 2009). The insular cortex is a recognized site
of autonomic cardiovascular control and BR-mediated autonomic
cardiovascular function (Saleh and Connell, 1998). In 1998, Braak
and Braak (1998) demonstrated a hierarchical progression of AD
pathology that includes the insular cortex in an early stage. This
insular involvement might lead to changes in cardiovascular and
autonomic control, andmight consequently affect the BR (Saleh and
Connell, 1998; Zhang et al., 1998).
Further circumstantial evidence is found in the effects of exer-
cise. Exercise improves cardiovascular function and BR (Monahan
et al., 2000). Exercise has also been shown to lower the risk of AD
(Buchman et al., 2012). Although direct associations between
exercise, BR, and AD risk have not been investigated, and BR could
be nomore than amarker of exercise, it can be hypothesized that BR
function is part of the causal pathway that links exercise to reduced
AD risk, or that augmented BR is a marker of beneﬁcial effects of
exercise on autonomic brain centers.
Here, we have also shown that treatment with cholinesterase
inhibitors augmented BR function in AD. This is in line with recent
ﬁndings that atropine, in a dose which augments vagal tone,
increased cardiovagal BR gain in older subjects (Callegaro and
Taylor, 2012). Our ﬁndings cannot be explained by age-related
effects only (Gribbin et al., 1971) because we compared AD and
MCI patients with age-matched healthy control subjects. Cholin-
esterase inhibitors partly compensate for the cholinergic deﬁcit in
AD. The cholinergic system has a pivotal role in learning and
memory (Robinson et al., 2011). However, the augmented BR
function suggests that cholinesterase inhibitors might slow clinical
disease progression not only through direct cognitive effects but
also through their inﬂuence on cardiovascular factors such as BP
regulation.
Our ﬁndingsmight extend to preclinical and early clinical AD, for
example, patients with MCI. Patients with MCI have a high risk of
progression to dementia, particularly of the Alzheimer type
(Rasquin et al., 2005; Winblad et al., 2004). There is a greater
orthostatic fall in SBP in MCI and Alzheimer patients than in control
subjects (Allan et al., 2007; Collins et al., 2012) and the prevalence
of orthostatic hypotension in MCI patients lies between control
subjects and AD patients (Mehrabian et al., 2010). This observation
parallels the BR values in control subjects, MCI, and AD found in our
study and is in line with an earlier study which showed an asso-
ciation between blunted BR functioning and increased risk of
orthostatic hypotension (La Rovere et al., 1998).
Despite the fact that several studies have shown an association
between AD and autonomic instability, such as increased pupillary
dilatation (Grunberger et al., 1999), diminished HR variability
(Giubilei et al., 1998), and orthostasis, the signiﬁcance of the
abnormalities in BR among AD patients is not yet fully known.
However, impaired BR in other common dementia subtypes, such
as Parkinson disease and Lewy body disease, is held partly
responsible for the higher prevalence of orthostatic hypotension
(Allan et al., 2007) and increased cardiovascular mortality. These
patients also exhibit a signiﬁcant loss of cholinergic forebrain
neurons (Aarsland et al., 2004).
4.2. BR functioning as a diagnostic tool
In the perspective of new therapeutic options to slow the
progression of dementia, an early diagnosis of AD is of utmost
importance because all treatment strategies are more effective in
the earlier phases of the disease (Polak et al., 2007). In this study,
a rapid, noninvasive, and inexpensive procedure without need for
active patient cooperation was used to estimate BR function from
ECG and BP recordings, obtained when the patient quietly sits orlies down. Our results show that in patients with AD, a lowered BR
could be a sensitive and speciﬁc marker of the disease. A strength of
the study is the consistent decrease in BR found over the different
groups (from healthy subjects to MCI patients to AD patients). This
result points toward a disease-speciﬁc involvement of the BR.
However, although we have shown that BR discriminates between
AD and control subjects, further evidence must be obtained for its
discriminatory value against important differential diagnoses in
memory clinics (i.e., other causes of dementia and depression).
4.3. Limitations
Some methodological issues need to be considered. First of all,
the diagnosis of AD and MCI in our study remains a clinical one.
There was no pathologic conﬁrmation of the underlying disease.
However, previous studies have shown that a clinical diagnosis is
only inaccurate, compared with pathologic diagnosis, in approxi-
mately 11% of mild cases (Salmon et al., 2002). The patients with
MCI and AD were diagnosed by a multidisciplinary memory clinic
team consisting of several geriatricians, neuropsychologists, occu-
pational therapists, and speech therapists. Lewy body dementia and
vascular dementia were excluded based on diagnostic criteria for
these conditions, using information obtained by means of history,
clinical examination, laboratory tests, and additional, mostly
radiologic, investigations. In a population referred to a memory
clinic (as in this study), depending on criteria, a high percentage of
MCI patients will develop AD (Palmer et al., 2007; Petersen et al.,
2001). Still, in some patients MCI remains stable and never pro-
gresses to AD. Therefore the assumption that abnormal BR function
serves as early detection of the Alzheimer disease process remains
hypothetical. To overcome this limitation, larger scale studies with
follow-up of MCI and AD patients are needed, with observations of
BR during the different stages of progression of AD. Maybe
a combination with other easy to determine parameters, in
particular the cerebrovascular resistance index (Gommer et al.,
2012), could enhance discrimination of patients at risk for devel-
oping AD.
Second, it might be argued that results should have been cor-
rected for differences in use of medication, because we included
patients with comorbidities and medication. There is some infor-
mation about whether commonly used antihypertensive agents,
such as metoprolol and enalapril, can augment the cardiac auto-
nomic function in hypertensive patients. Keeley et al. (1996)
showed that b-blockers can directly improve cardiovascular auto-
nomic regulation in normotensive and hypertensive patients
(Keeley et al., 1996). Further, Mancia et al. (1982) showed an
increase in BR function when the circulating levels of angiotensin II
and aldosterone were reduced by angiotensin-converting enzyme
inhibitors. Because antihypertensive drugs mostly show an increase
of the BR function, we argue that the difference in BR function
between AD patients and healthy elderly would have been even
greater when the AD patients had used no antihypertensive agents.
Third, some differences exist in population and protocol char-
acteristics between the derivation and validation sample. In the
validation sample the control subjects had a higher SBP (136 mm
Hg compared with 125 mm Hg) than in the derivation sample.
Furthermore, in the derivation sample BP and HR were obtained in
the sitting position, in the validation sample BP and HR were ob-
tained supine. These differences might explain the difference in BR
between the 2 control groups (6.4 ms/mm Hg in the derivation
sample versus 3.6 ms/mm Hg in the validation sample). Bristow
et al. (1969) showed an inverse relationship between resting
mean BP and BR, with reduced BR sensitivity in hypertension. This
might explain the observed lower BR in the derivation sample
where the SBP was higher. However, literature yields discordant
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et al., 1995; Wichterle et al., 2000).
Finally, a limitation of the study is the cross-sectional design.
This design allows us to establish the relationship between BR and
AD, but we are unable to establish whether the impaired func-
tioning of the BR is the effect or the cause of neurodegeneration.
5. Conclusions
This study shows a strong association between AD and dimin-
ished BR function. A possible link is the cholinergic systemwhich is
involved in both BR and AD. Cholinesterase inhibitors increase BR
function in AD. Furthermore, MCI patients have an intermediate BR
function between the normal and the AD subjects. Considering this,
it is possible that early in AD besides cognition also BP regulation is
affected. Further research on the relationship between BR and AD
might provide valuable insights into the pathophysiology and for
the diagnosis and treatment of AD.
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